Rose McNulty

Adverse events related to the immune system tended to accumulate over time when patients used immune checkpoint inhibitors (ICIs) over time.

Although overall costs have not declined with the Oncology Care Model (OCM), supportive care costs have decreased through greater use of cost-effective therapies.

An eHealth survey revealed widespread confusion, low awareness of 2026 Medicare plan changes, and growing interest in artificial intelligence support.

Vivek Subbiah, MD, considers artificial intelligence (AI) and comprehensive somatic and germline testing essential for guiding precision oncology and improving patient care.

UC Davis pharmacy residents research medication management and patient care, focusing on how pharmacists improve outcomes and reduce readmissions, according to Jeremiah J. Duby, PharmD, BCPS, BCCCP.

The Trump administration advances the Most Favored Nation order by partnering with Pfizer, which came to the table voluntarily and has been granted a reprieve from upcoming drug tariffs.

Biomarkers like neutrophil-to-lymphocyte ratio could help predict treatment response to immune checkpoint inhibitors in certain patients with soft tissue sarcoma.

A wearable cough monitor generated clinically useful cough data, but patients only wore the device about half of the days of the study period.

The approval of remibrutinib for patients with chronic spontaneous urticaria was supported by data from the phase 3 REMIX-1 and REMIX-2 clinical trials.

Patients with immunoglobulin M-type monoclonal gammopathy did not experience a survival benefit from targeted therapies, a study found.

Paternal prepubertal passive smoke exposure is linked to impaired lung function trajectories in offspring, persisting into adulthood.

Second primary malignancies in patients with small cell lung cancer are often misdiagnosed as distant metastases.

Electronic health record (EHR)–based “e-phenotypes” combining lab data, coding, and AI could dramatically improve early detection and management of chronic kidney disease.

Emma Guttman-Yassky, MD, PhD, discusses the long-term efficacy of deuruxolitinib in alopecia areata.

Research exploring protective mechanical ventilation strategies for acute respiratory distress syndrome was presented at the ERS Congress by Luca Menga, MD, University of Toronto.

Guselkumab becomes the first interleukin-23 inhibitor approved for children with plaque psoriasis or active psoriatic arthritis.

Ana Baramidze, MD, head of the Department of Clinical Researches at the Todua Clinic in Tbilisi, Georgia, explained how clinicians can decide how to cemiplimab, which has a low discontinuation rate.

Atezolizumab or durvalumab, combined with platinum-doublet regimens, delivered superior responses and survival in patients often excluded from clinical trials.

High-risk patients who cannot find a matched sibling or matched unrelated donor may achieve a similar benefit from a haploidentical donor.

Oral upadacitinib combined with topical ruxolitinib cream may be a promising therapeutic approach for patients with progressive nonsegmental vitiligo.

Treating constipation with lubiprostone may confer renal benefits in chronic kidney disease by modulating microbiome-driven pathways.

Findings suggest bispecific CD3xCD20 therapy may offer an option for patients with Richter syndrome who are ineligible for transplant or CAR T-cell Therapy.

A recent study outlines how artificial intelligence advancements are transforming research and therapeutic strategies for idiopathic pulmonary fibrosis.

The study confirms that biologics are highly effective in real-world HS management, and highlights the need for a comprehensive treatment strategy considering both skin symptoms and systemic health.

A phase 1b trial of tarlatamab plus PD-L1 inhibitors in extensive-stage small-cell lung cancer (ES-SCLC) showed a median overall survival of 25.3 months with manageable safety.

Patients with essential thrombocythemia live with a risk of developing serious bleeding complications, a new study explains.

Multidisciplinary care influenced therapy choices but did not substantially shorten treatment delays for patients with sarcoma.

A case series suggests using minimal residual disease to trigger anti-CD20 therapy for chronic lymphocytic leukemia (CLL) can add years to some patients’ lives.

Artificial intelligence (AI) holds the potential to democratize precision oncology, but it must be implemented thoughtfully.

The approval of paltusotine (Palsonify; Crinetics) marks the first for a once-daily, oral therapy to treat acromegaly.